Low Testosterone Lawsuit: JAMA Study Details

September 23, 2015 – – Banville Law reports on a litigation that appears to have been started by the epidemiology studies conducted in the Journal of American Medicine. In March of 2015, federal lawsuits filed against many manufacturers of low testosterone drugs were consolidated into a Multidistrict Litigation (MDL) in the U.S. District Court for the Northern District of Illinois, to be presided over by the Honorable Judge Matthew F. Kennelly.

As this MDL is now made up of over 2,500 plaintiffs, it also consists of multiple defendants, beginning with Abbvie and Abbott Laboratories, the manufacturers of AndroGel. Amidst the many serious allegations, sales of low t drugs and gels are projected to soar to $5 billion over the next two years.

The MDL panel noted that many of the individual victims’ claims involved common scientific facts, side effect complaints, and theories. In general, the claims allege that after being prescribed low t therapies, the plaintiffs suffered from a range of serious health issues, including blood clots, strokes, heart attacks, and even death.

The first lawsuits filed in this litigation appeared just a few days after the Food and Drug Administration (FDA) stated its intention to re-evaluate the drug’s safety. This action closely followed studies from the Journal of American Medicine which took place in late 2013 and seemed to show evidence linking low t drugs to elevated risks of pulmonary embolisms, deep vein thrombosis, strokes, heart attacks, and death.

Overall, the study’s findings indicated that men taking prescription low T supplements had about 30% higher chances of suffering from serious heart issues. After an additional PLOS ONE testosterone study took place, it seemed as well, that men over 65 were at a much greater risk of these occurrences, specifically up to 3 times more.

There are many popular drugs currently used to treat low t which are now under close watch. These include AndroGel, Androderm, Android, Axiron, Depo-Testosterone, Fortesta, Striant, and Testim. They range in form, from pills to gels or injections.

Testosterone therapy treatments through these drugs were created and approved to treat men with diagnosed medical conditions, specifically hypogonadism, a rare condition where the man’s body does not produce enough testosterone. Plaintiffs allege, however, that the medications are instead advertised as ways for any aging man to reinvigorate themselves, both physically and sexually, and feel younger again.

Several medical reports also seem to indicate that many of the men who begin low t treatments are never tested for low testosterone levels beforehand, as the FDA specifically approved the products for.

For more information on this topic or details about seeking legal options, contact Laurence Banville, Esq. of Banville Law. Laurence is currently working to assist individuals who may be struggling with health issues after taking low testosterone drugs. Additionally, he is a sponsor of LowTestosteroneCase.com, where those interested can find more details regarding this issue and their rights. To speak with Laurence Banville, Esq. directly, please contact 917-809-6595 today.

###

Contact Banville Law:

Laurence Banville, Esq.
888-478-9711
info@banvillelaw.com
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60004347